Petmed Express Inc (NASDAQ:PETS) has been assigned an average rating of “Sell” from the six brokerages that are covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating and two have given a hold rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is $32.00.
Several research firms have weighed in on PETS. ValuEngine raised shares of Petmed Express from a “strong sell” rating to a “sell” rating in a research report on Friday, October 26th. BidaskClub downgraded shares of Petmed Express from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 15th. Finally, TheStreet downgraded shares of Petmed Express from a “b” rating to a “c+” rating in a research report on Thursday, November 29th.
A number of hedge funds and other institutional investors have recently made changes to their positions in PETS. Epoch Investment Partners Inc. acquired a new stake in Petmed Express during the 2nd quarter valued at approximately $22,044,000. Newtyn Management LLC acquired a new stake in Petmed Express during the 2nd quarter valued at approximately $12,114,000. BlackRock Inc. lifted its stake in Petmed Express by 9.8% during the 2nd quarter. BlackRock Inc. now owns 2,917,663 shares of the company’s stock valued at $128,523,000 after acquiring an additional 260,789 shares during the period. Morgan Stanley lifted its stake in Petmed Express by 110.1% during the 3rd quarter. Morgan Stanley now owns 312,416 shares of the company’s stock valued at $10,313,000 after acquiring an additional 163,691 shares during the period. Finally, New Amsterdam Partners LLC NY acquired a new stake in Petmed Express during the 3rd quarter valued at approximately $3,341,000. Institutional investors and hedge funds own 95.04% of the company’s stock.
NASDAQ PETS traded down $0.32 during trading on Friday, reaching $22.43. 433,125 shares of the company’s stock traded hands, compared to its average volume of 586,929. Petmed Express has a 12-month low of $21.85 and a 12-month high of $57.80. The company has a market capitalization of $502.79 million, a price-to-earnings ratio of 11.69 and a beta of 0.74.
Petmed Express (NASDAQ:PETS) last issued its quarterly earnings data on Monday, October 22nd. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.50 by $0.02. Petmed Express had a net margin of 14.88% and a return on equity of 35.53%. The firm had revenue of $71.40 million for the quarter, compared to the consensus estimate of $71.93 million. During the same quarter in the previous year, the firm earned $0.43 EPS. The company’s quarterly revenue was up 7.0% compared to the same quarter last year.
Petmed Express Company Profile
PetMed Express, Inc and its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. It markets prescription and non-prescription pet medications, and other health products for dogs and cats directly to the consumers. The company offers non-prescription medications and supplies, including flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, such as heartworm preventative, flea and tick preventative, arthritis, thyroid, diabetes, pain, heart/blood pressure, and other specialty medications, as well as generic substitutes.
See Also: Capital gains and your 401(k) or IRA
Receive News & Ratings for Petmed Express Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Petmed Express and related companies with MarketBeat.com's FREE daily email newsletter.